Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes.
The biological effects of epidermal growth factor receptor (EGFR) activation may differ between epidermal suprabasal and basal keratinocytes, since growth factors are mitogenic in adherent cells only in the presence of cell-extracellular matrix (ECM) interaction. To investigate biological effects of EGFR activation on keratinocytes without cell-ECM interaction, we cultured normal human keratinocytes on polyhydroxyethylmethacrylate-coated plates, which disrupt cell-ECM but not cell-cell interaction. The cells initially expressed keratin 10 (K10) and then profilaggrin, mimicking sequential differentiation of epidermal suprabasal keratinocytes. The addition of EGF or transforming growth factor-alpha promoted late terminal differentiation (profilaggrin expression, type 1 transglutaminase expression and activity, and cornified envelope formation) of the suspended keratinocytes, while suppressing K10 expression, an early differentiation marker. These effects were attenuated by EGFR tyrosine kinase inhibitor PD153035 or an anti-EGFR monoclonal antibody, whereas protein kinase C inhibitors H7 and bisindolylmaleimide I or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 abolished profilaggrin up-regulation but not K10 suppression. Since the antidifferentiative role of EGFR on cell-ECM interaction-conserved keratinocytes has been well documented, our results indicate that the biological effects of EGFR on keratinocytes are influenced by cell-ECM interaction and suggest that EGFR activation promotes rather than inhibits the terminal differentiation of suprabasal epidermal keratinocytes.
Wakita
H
H
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan. wakita@hama-med.ac.jp
Takigawa
M
M
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000494:pharmacology; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D004789:Enzyme Activation; D004815:Epidermal Growth Factor / Q000494:pharmacology; D066246:ErbB Receptors / Q000502:physiology*; D005109:Extracellular Matrix / Q000502:physiology*; D000091344:Filaggrin Proteins; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D007381:Intermediate Filament Proteins / Q000096:biosynthesis; D015603:Keratinocytes / Q000502:physiology*; D007633:Keratins / Q000096:biosynthesis; D051379:Mice; D011493:Protein Kinase C / Q000502:physiology; D011498:Protein Precursors / Q000096:biosynthesis; D011503:Transglutaminases / Q000096:biosynthesis
D000091344:Filaggrin Proteins; D005419:Flavonoids; D007381:Intermediate Filament Proteins; D011498:Protein Precursors; D004815:Epidermal Growth Factor; D007633:Keratins; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D011503:Transglutaminases; D066246:ErbB Receptors; D011493:Protein Kinase C; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one